Kaftrio* (elexacaftor/tezacaftor/ivacaftor)

Kaftrio* (elexacaftor/tezacaftor/ivacaftor) is a medication used in combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

Ivacaftor 150 mg tablets are not included in the package, they are available to order here

The medicine is approved by the Food and Drugs Administration (FDA) under the brand-name Trikafta. We have it available to order as well. See [Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor)].

Please note that we have a generic form of edaravone available to order as well. See [Trixacar (elexacaftor/tezacaftor/ivacaftor; ivacaftor)].

• are aged over 6
• have two copies of the F508del mutation or one copy of F508del and any other mutation.

The various drug regulatory bodies across the world take different approaches to how they interpret evidence on the safety and clinical effectiveness of new drugs and ultimately what licence indication should be granted. In the UK, the MHRA is the regulator which makes these decisions.

There may be other reasons why someone is not able to benefit from Kaftrio. We have a factsheet on the complex and individual experiences around Kaftrio, for those who are taking it, as well as those who are not.